MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops...
17 insider purchases on record · latest filing 2023-10-16.
Insiders have also filed 10 sale transactions at INKT.